News

Psoriasis severity linked to uncontrolled hypertension


 

References

The more severe the psoriasis, the greater likelihood of uncontrolled hypertension, according to data from a population-based study. The findings were published online Oct. 15 in JAMA Dermatology.

In patients with diagnosed hypertension, those with moderate to severe psoriasis showed a positive dose-response relationship between their psoriasis activity and high blood pressure, wrote Dr. Junko Takeshita of the University of Pennsylvania, Philadelphia, and her associates (JAMA Dermatol. 2014 Oct. 15 [doi:10.1001/jamadermatol.2014.2094]).

The researchers compared a random sample of 1,322 adults aged 25-64 years with psoriasis and hypertension and 11,977 age- and practice-matched controls with hypertension. The data were taken from a population-based, cross-sectional study nested in a prospective cohort drawn from an electronic medical records database in the United Kingdom.

After investigators adjusted for age, sex, body mass index, smoking and alcohol use status, presence of comorbid conditions, and current use of antihypertensive medications and nonsteroidal anti-inflammatory drugs, they found psoriasis activity and uncontrolled hypertension correlated, with adjusted odds ratios of 0.97 for mild psoriasis,1.20 for moderate psoriasis, and 1.48 for severe psoriasis (P = .01). The likelihood of uncontrolled hypertension among psoriasis overall was also increased, but this increase was not statistically significant.

The study was limited by its cross-sectional design, which make the directionality of the two conditions hard to determine, the researchers noted.

However, the findings suggest that, among patients with hypertension, psoriasis “is independently associated with poorly controlled blood pressure,” and that more effective blood pressure management is warranted in psoriasis patients, especially those with more severe disease.

Dr. Takeshita reported receipt of payment for continuing medical education work related to psoriasis. Coauthor Dr. Joel Gelfand reported serving as a consultant for AbbVie, Amgen, Celgene, Eli Lilly, Janssen Biologics, and others. This study was supported in part by the National Heart, Lung, and Blood Institute and the National Institute of Arthritis and Musculoskeletal and Skin Diseases.

wmcknight@frontlinemedcom.com

On Twitter @whitneymcknight

Recommended Reading

Anti-adalimumab antibodies mean poorer outcomes in psoriatic arthritis
MDedge Family Medicine
Psoriasis patients post above-average cancer rates
MDedge Family Medicine
Jury still out on effect of systemic psoriasis meds on MI risk
MDedge Family Medicine
Psoriatic arthritis patients often changed or stopped treatment
MDedge Family Medicine
Minimal disease activity in psoriatic arthritis is a realistic target
MDedge Family Medicine
Apremilast approval expanded to include plaque psoriasis
MDedge Family Medicine
Specialty drug coupons - a double-edged sword of improved adherence, increased costs
MDedge Family Medicine
Drug combos for psoriatic arthritis upped shingles risk
MDedge Family Medicine
High-resolution MRI revealed enthesitis in PsA patients with dactylitis
MDedge Family Medicine
VIDEO: Dr. Alan Menter discusses apremilast’s approval for psoriasis
MDedge Family Medicine